What does the evidence show about Huperzine A's effects?

Read Off Label rates the evidence for Huperzine A as Moderate and the benefit magnitude as med, producing an overall grade of B- (6.3/10). Extensively studied in China for AD/MCI.

What safety findings are reported for Huperzine A?

Huperzine A has a low-med risk profile in the database. Low-Med (cholinergic effects: GI upset, cramping, vivid dreams; bradycardia at high doses) Legal status: OTC in US; Rx in China.

Rankings / Cognitive

Huperzine A

Cognitive · AChE inhibitor (natural)

Tier B-

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

cholinergicnmda-modulatorotc

6.3 / 10

Tier B-

Ev 6 Bn 5 Sf 7

Bottom line

Read Off Label grades Huperzine A as B- (6.3/10) based on moderate evidence, med benefit magnitude, and a low-med-risk safety profile.

Extensively studied in China for AD/MCI.

Studied, labeled, or reported-use context: 50-400 mcg/day PO; cycling common — OTC in US; Rx in China; not individualized guidance.

What the evidence says

Extensively studied in China for AD/MCI. AChE inhibition lasts about 24 hours; cycling is reported in consumer protocols but has not been validated for preventing tolerance. Concurrent exposure with prescription AChE inhibitors can increase cholinergic adverse effects.

Mechanism

Reversible, selective acetylcholinesterase inhibitor from Chinese club moss (Huperzia serrata); also NMDA antagonist and neuroprotective activity

Studied, labeled, or reported dose & route

50-400 mcg/day PO; cycling common

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Huperzine A's effects?: Read Off Label rates the evidence for Huperzine A as Moderate and the benefit magnitude as med, producing an overall grade of B- (6.3/10). Extensively studied in China for AD/MCI.
What safety findings are reported for Huperzine A?: Huperzine A has a low-med risk profile in the database. Low-Med (cholinergic effects: GI upset, cramping, vivid dreams; bradycardia at high doses) Legal status: OTC in US; Rx in China.
What doses or routes are reported for Huperzine A?: 50-400 mcg/day PO; cycling common This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Huperzine A work?: Reversible, selective acetylcholinesterase inhibitor from Chinese club moss (Huperzia serrata); also NMDA antagonist and neuroprotective activity

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.